Cooley advised Prana Therapies, a clinical-stage biotechnology company pioneering next-generation half-life-extended multispecific antibodies, on its agreement to be acquired by Bolt Biotherapeutics, a clinical-stage biotechnology company pioneering a new generation of half-life-extended multispecific antibodies.
Cooley Advised Prana Therapies on Agreement to Be Acquired By Bolt Biotherapeutics